Skip to main content

Brand new biomanufacturing space, now under construction


Available Q1 2023

A quality home for Biomanufacturing

149 Hayes is designed for complex GMP technologies and processes.

140 k SF in Marlborough, MA

Make your mark in a newly built space. This goods manugacturing and production (GMP) facility offers economic efficiency with plenty of room for growth. Construction will finish in late 2022, providing an opportunity for your production to start in 2023. The two-storey, 24-acre development is in the heart of the dynamic Marlborough Life Sciences cluster, an existing industrial corridor with a thriving innovation and biotechnology community.

Located minutes away from the I-495 makes the property highly convenient for transportation needs. Its close proximity to R&D hubs in the Boston market, alongside an array of popular amenities, amplifies its potential to attract high-quality talent.

Building Specs

140,000 SF Total

• 100,000 SF first floor
• 40,000 SF second floor

36' Maximum clear height

• 18' Minimum clear height
• 40' x 45' approximate bay spacing

4 Exterior tailboard height loading docks

• 1 additional 10' x 12' drive-in door

2 Freight elevators

• 3,500 lb and 5,000 lb max capacity

6,000 Amps of electricity

140,000 SF Total

• 100,000 SF first floor
• 40,000 SF second floor

36' Maximum clear height

• 18' Minimum clear height
• 40' x 45' approximate bay spacing

4 Exterior tailboard height loading docks

• 1 additional 10' x 12' drive-in door

2 Freight elevators

• 3,500 lb and 5,000 lb max capacity

6,000 Amps of electricity

BrochureSite PlanTour Deck & Floor PlansConnect
149hayes.jpg

Connect to book a tour or learn more

Oxford Properties Group

Matthew Polhemus
Director, Leasing
mpolhemus@oxfordproperties.com

JLL

Sam Crossan
Senior Vice President
sam.crossan@am.jll.com
+1 617.316.6496

About us

Oxford Properties Group

As a leading global real estate business, Oxford currently oversees more than 3 million SF of Life Sciences space across a mix of managed properties and development projects. We provide the platforms, amenities and services Life Sciences companies need to grow and prosper. Our fully integrated, global portfolio supports business at all stages of work in the sector, from early research and development through to production and manufacturing. In the US, Oxford’s Life Sciences portfolio is supported by expert on-the-ground presence in Boston, San Francisco, Washington DC and New York. Oxford is owned by OMERS, the defined benefit pension plan for over 500,000 of Ontario’s municipal employees with $90B in net assets.